- Home
- Companies
- Rani Therapeutics
- Articles
- Rani Therapeutics Debuts on the Nasdaq: ...
Rani Therapeutics Debuts on the Nasdaq: What uou should know About the Biopharma
IMPORTANT MESSAGE: Benzinga prides itself as a media platform that is "For the People, By the People." We understand the markets are scary right now. For that reason, we are here to help. For today only get access to our #1 Options Newsletter for only $1.
Rani Therapeutics Holdings, Inc.
Rani Shares Trade Around IPO Price: Rani shares opened for trading at $11.26, above the IPO price of $11. Since then, the stock has traded in a $10.50-$12.17 range.
The company offered 6.67 million shares of its Class A common stock through the IPO, which was conducted through an "Up-C" structure.
Rani was initially structured as a LLC, and the "Up-C" structure is a fairly a standard way of taking a LLC public, CEO Talat Imran said in an exclusive chat with Benzinga.
Rani, A Platform Technology Company: Rani`s proprietary platform technology, the RaniPill capsule, intends to replace subcutaneous or intravenous injections of biologics with oral dosing.
RaniPill helps convert injectable biologic drugs such as TNF-alpha inhibitors, interleukin antibodies and basal insulin, among others, into pills.
"Our mission is to, at the minimum give an alternative to, and hopefully end injections for patients who have to do that on a chronic basis, Imran said.
For IV infusions, a patient has to go to hospitals every time, and in the case of self-injected options, they will have to find vessels every time, he said.
Rani`s Pipeline: Rani has a candidate codenamed RT-10 in Phase 1 development for acromegaly, a hormonal disorder. The company has five preclinical compounds evaluated for different indications.
Rani has completed a Phase 1 single-dose study completed in Australia, and a paper has been published on the findings from the preclinical and clinical study, Imran told Benzinga.
The company plans to go to the FDA for guidance on how the future studies should look.
In comparison with approved medications, Imran said, Rani`s approach to deliver biologics orally yields bioavailability and absorption similar to subcutaneous injections in the range of 40%-80%, depending on the drug.
RT-101 is being evaluated for acromegaly, and Rani expects to run trials for neuroendocrine tumor of the gastrointestinal tract as well as carcinoid syndrome, the CEO said.
Imran qualified the market potential for RT-101 in all the three indications as "significant."
Rani looks ahead to launching Phase 1 study of para thyroid hormone for the treatment of osteoporosis.
The biopharma has ongoing clinical collaborations with Novartis AG
Rani`s Cash Runway: Rani is confident that it can achieve the objectives laid down in the prospectus, Imran said.
"We have the capital to execute against the plan," the CEO said.
"Rani is a mission-driven company and our goal is to take these biologic drugs that have to be injected frequently and turn them into pills and give patients an alternative."
At last check, Rani shares were down 1.36% at $10.85.
Related Link: How Much A $1,000 Investment In Moderna Stock At the Time Of COVID-19 Vaccine Authorization Would Be Worth Today
If you are not using this trading strategy, you are leaving money on the table...
If you are blindly looking up and trading stocks the way 99% of traders are, you are missing on HUGE potential returns. Even new traders who started following this options trading strategy instantly began seeing a new perspective in how the markets move. With even two trades per month with this strategy, you will start seeing the difference in your trading strategies. Don`t waste any more time "guessing" and "getting lucky". Click Here Now to See if You Qualify!
If you are a new trader then you need to read this...
Most new traders struggle at first to make sense of the markets and how to put their portfolio in a position to flourish. Many try to start on their own and quickly end up with a string of losses, slowly seeing their accounts dwindle to what it started off as... Don`t let this happen to you. By joining a vetted educational platform built for new traders, you will be taken step by step by a former hedge fund trader who managed billions of dollars. This is exactly what Benzinga Trading School is doing by helping traders overcome the initial challenges and to help them thrive and to learn how professionals earn a consistent profit in any market condition. For today only, you can try Benzinga Trading School yourself for 7 days risk free.